Free Trial

Pro-Dex (PDEX) Competitors

Pro-Dex logo
$47.27 -0.26 (-0.55%)
Closing price 07/17/2025 04:00 PM Eastern
Extended Trading
$48.51 +1.24 (+2.63%)
As of 07/17/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDEX vs. EMBC, BBNX, AVNS, BVS, KIDS, RXST, AXGN, BFLY, SMLR, and DCTH

Should you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include Embecta (EMBC), Beta Bionics (BBNX), AVANOS MEDICAL (AVNS), Bioventus (BVS), OrthoPediatrics (KIDS), RxSight (RXST), AxoGen (AXGN), Butterfly Network (BFLY), Semler Scientific (SMLR), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.

Pro-Dex vs. Its Competitors

Pro-Dex (NASDAQ:PDEX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Pro-Dex presently has a consensus price target of $56.00, suggesting a potential upside of 18.47%. Embecta has a consensus price target of $19.00, suggesting a potential upside of 92.89%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than Pro-Dex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pro-Dex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Embecta
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Pro-Dex has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Pro-Dex has a net margin of 14.61% compared to Embecta's net margin of 4.89%. Pro-Dex's return on equity of 29.08% beat Embecta's return on equity.

Company Net Margins Return on Equity Return on Assets
Pro-Dex14.61% 29.08% 16.19%
Embecta 4.89%-19.67%12.27%

Embecta has higher revenue and earnings than Pro-Dex. Embecta is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pro-Dex$53.84M2.86$2.13M$2.8016.88
Embecta$1.12B0.51$78.30M$0.9010.94

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 47.5% of Pro-Dex shares are held by insiders. Comparatively, 0.4% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Embecta had 4 more articles in the media than Pro-Dex. MarketBeat recorded 5 mentions for Embecta and 1 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.94 beat Embecta's score of 0.54 indicating that Pro-Dex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pro-Dex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Embecta
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Pro-Dex beats Embecta on 9 of the 15 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PDEX vs. The Competition

MetricPro-DexMED/DENTAL IndustryMedical SectorNASDAQ Exchange
Market Cap$155M$15.49B$5.56B$9.34B
Dividend YieldN/A1.46%3.80%4.06%
P/E Ratio16.8818.3328.0819.86
Price / Sales2.862.29433.4499.92
Price / Cash49.6416.9435.8457.94
Price / Book5.233.788.255.67
Net Income$2.13M$430.42M$3.24B$257.80M
7 Day Performance5.02%-0.32%1.43%1.87%
1 Month Performance15.74%1.35%8.02%10.92%
1 Year Performance145.56%15.85%30.07%18.51%

Pro-Dex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PDEX
Pro-Dex
2.1858 of 5 stars
$47.27
-0.5%
$56.00
+18.5%
+137.5%$155M$53.84M16.88140
EMBC
Embecta
4.6885 of 5 stars
$10.03
-2.8%
$19.33
+92.8%
-27.6%$603.13M$1.08B11.142,100Analyst Forecast
BBNX
Beta Bionics
N/A$13.40
-0.9%
$23.44
+75.0%
N/A$586.18M$65.12M0.00294Positive News
AVNS
AVANOS MEDICAL
2.8844 of 5 stars
$11.87
-3.9%
N/A-48.6%$571.11M$687.80M-1.422,227
BVS
Bioventus
2.7668 of 5 stars
$6.82
-2.8%
$13.75
+101.6%
-9.4%$560.22M$567.70M-11.181,200
KIDS
OrthoPediatrics
4.2487 of 5 stars
$21.24
-5.5%
$35.83
+68.7%
-36.0%$545.96M$204.73M-12.14200
RXST
RxSight
2.2897 of 5 stars
$12.43
-4.8%
$37.90
+204.9%
-84.4%$530.31M$139.93M-18.55220Analyst Downgrade
AXGN
AxoGen
2.1928 of 5 stars
$11.36
+3.9%
$24.50
+115.7%
+22.7%$497.80M$187.34M-75.73450News Coverage
Analyst Revision
High Trading Volume
BFLY
Butterfly Network
2.5573 of 5 stars
$1.89
-2.6%
$3.50
+85.2%
+55.4%$479.74M$82.06M-6.52460
SMLR
Semler Scientific
2.6307 of 5 stars
$38.95
-3.7%
$71.00
+82.3%
+20.4%$451.08M$56.29M-14.92120
DCTH
Delcath Systems
2.6119 of 5 stars
$12.24
-3.5%
$24.00
+96.1%
+44.8%$441.94M$37.21M-24.4860News Coverage

Related Companies and Tools


This page (NASDAQ:PDEX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners